How to Get Tresiba (Insulin Degludec) in Michigan

What Is Tresiba and Why Do Michigan Patients Seek It?

Tresiba is a once-daily basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours, making it the longest-acting basal insulin currently approved by the FDA [1]. Michigan patients with type 1 or type 2 diabetes often request it specifically because its ultra-flat pharmacokinetic profile produces less day-to-day glucose variability than insulin glargine U-100 or insulin detemir [2]. The SWITCH 1 trial (N=501, type 1 diabetes) demonstrated a statistically significant reduction in overall hypoglycemia rate with degludec versus glargine (rate ratio 0.89, P<0.05) [3].

Insulin degludec forms soluble multi-hexamers after subcutaneous injection, which slowly dissociate to release monomers into the bloodstream [4]. That mechanism is why the coefficient of variation for its glucose-lowering effect is roughly 20 percent lower than glargine U-100. For Michigan patients who experience early-morning hypoglycemia on glargine, this pharmacological difference is clinically meaningful.

The FDA approved Tresiba in September 2015 for adults, and later expanded the label to patients as young as one year of age [1]. Novo Nordisk manufactures it in two concentrations: U-100 (FlexTouch pen, 3 mL) and U-200 (FlexTouch pen, 3 mL, delivering up to 160 units per injection). Both are available at licensed Michigan pharmacies.

How to Get a Tresiba Prescription in Michigan

Any Michigan-licensed prescriber with DEA registration and authority to manage diabetes can write a Tresiba prescription. The three fastest paths are an in-person endocrinology or primary care visit, a scheduled telehealth visit through a Michigan-registered platform, or a transfer of an existing prescription from another state.

Before writing the prescription, your provider will typically review a recent HbA1c, a fasting glucose log, current insulin regimen and total daily dose, renal function (eGFR), and any history of severe hypoglycemia [5]. These are not arbitrary bureaucratic steps; Michigan Medicaid and most commercial payers require documented clinical necessity before approving Tresiba over a preferred basal insulin such as glargine biosimilars.

The American Diabetes Association 2024 Standards of Care state: "Insulin degludec and glargine U-300 are associated with less nocturnal hypoglycemia than glargine U-100 and may be preferred in patients at high hypoglycemia risk" [6]. That language gives prescribers a clear, guideline-backed rationale to document in the chart.

Once the clinical note is complete, your prescriber submits the prescription electronically to your preferred pharmacy or initiates a prior authorization if your plan requires one. Mail-order specialty pharmacies licensed in Michigan can ship Tresiba directly to your home, often within two to five business days of PA approval.

Telehealth Options for Tresiba in Michigan

Michigan law permits telehealth prescribing of non-controlled substances, and insulin degludec is not a controlled substance [7]. A licensed Michigan telehealth provider may conduct a synchronous audio-video visit, review your diabetes records and glucose data, and transmit a Tresiba prescription to any in-state or mail-order pharmacy on the same day as the visit.

Telehealth visits for basal insulin management typically run 20 to 30 minutes. The provider will ask you to share recent glucose logs or continuous glucose monitor (CGM) data, your current total daily insulin dose, and any recent labs. CGM data from a Dexcom G7 or Libre 3 can be shared via the manufacturer's clarity portal before the visit, which saves time and improves prescribing accuracy [8].

HealthRX connects Michigan patients with board-certified physicians and advanced practice providers who have direct experience titrating basal insulins. After a telehealth visit, the prescription is transmitted electronically to your pharmacy of choice.

The table below is HealthRX's internal clinical intake framework for basal insulin telehealth visits in Michigan. It reflects the documentation most Michigan commercial payers and Medicaid require for a successful prior authorization.

HealthRX Michigan Basal Insulin Telehealth Intake Checklist

| Item | Minimum Requirement | |---|---| | HbA1c | Drawn within the past 90 days | | Fasting glucose logs | At least 7 days of morning readings | | Current insulin regimen | Total daily dose and injection timing documented | | eGFR / creatinine | Drawn within the past 12 months | | Hypoglycemia history | Any level 2 (<54 mg/dL) or level 3 events in past 6 months | | CGM data (if applicable) | 14-day ambulatory glucose profile preferred | | Prior basal insulin trials | Name, dose, duration, reason for discontinuation |

What Labs Are Required Before Starting Tresiba in Michigan?

Labs are straightforward. HbA1c drawn within 90 days is the single most important result, because it establishes glycemic baseline and justifies the need for basal insulin therapy [6]. Most payers also want a fasting glucose or a 7-day glucose log to confirm that fasting hyperglycemia is the primary uncontrolled parameter.

Renal function matters because patients with eGFR <30 mL/min/1.73m² may need closer dose titration and more frequent monitoring; insulin clearance can be altered in severe kidney disease [5]. The Tresiba prescribing information notes no specific dose adjustment by renal stage, but the FDA label recommends frequent glucose monitoring in patients with renal impairment [1].

Liver function tests are not routinely required unless the patient has known hepatic disease. A lipid panel and thyroid function test are reasonable additions at a new-patient diabetes visit but are not payer-required for a Tresiba PA specifically [6].

Michigan Medicaid Coverage and Prior Authorization for Tresiba

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid) covers insulin degludec with prior authorization for both type 1 and type 2 diabetes [9]. The PA criteria typically require documentation of: a confirmed diabetes diagnosis (type 1 or type 2), current HbA1c value, at least one trial of a preferred basal insulin (usually glargine U-100 or a biosimilar) unless contraindicated, and clinical rationale for why degludec is medically necessary over the preferred agent.

Acceptable rationale includes documented recurrent nocturnal hypoglycemia on glargine, HbA1c above goal despite maximized glargine dosing, or clinical preference for U-200 concentration in an insulin-resistant patient requiring more than 80 units of basal insulin daily [9]. Providers should include the specific event dates and glucose values for any hypoglycemia episodes in the PA letter.

Commercial payers in Michigan, including Blue Cross Blue Shield of Michigan, Priority Health, and McLaren Health Plan, have varying tier placements for Tresiba. Many place it on Tier 3 or Tier 4 with a step-therapy requirement. The PA process typically takes 24 to 72 business hours once a complete request is submitted [10].

If PA is denied, Michigan residents have the right to appeal and to request an expedited appeal if the denial creates a clinical urgency. A prescriber's letter citing the ADA 2024 Standards of Care and specific hypoglycemia event data carries significant weight in appeal reviews.

Clinical Evidence Supporting Tresiba

The DEVOTE trial (N=7,637) published in the New England Journal of Medicine in 2017 is the largest cardiovascular outcomes trial for insulin degludec [11]. It randomized patients with type 2 diabetes at high cardiovascular risk to degludec or glargine U-100, titrated to a fasting glucose target of 71 to 90 mg/dL. Degludec was non-inferior to glargine for major adverse cardiovascular events (MACE: hazard ratio 0.91 to 95% CI 0.78 to 1.06). Degludec also produced a 40 percent lower rate of severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) [11].

The SWITCH 2 trial (N=721, type 2 diabetes) confirmed a lower rate of overall symptomatic hypoglycemia with degludec versus glargine U-100 (rate ratio 0.70, P<0.001) during the maintenance phase [12]. These are not surrogate-endpoint studies; hypoglycemia rate reductions in DEVOTE and SWITCH 2 represent clinically meaningful differences in patient safety.

For type 1 diabetes, the SWITCH 1 trial (N=501) showed that patients crossing over from glargine to degludec achieved a lower rate of overall confirmed hypoglycemia and significantly fewer nocturnal confirmed hypoglycemic episodes [3]. The difference was most pronounced in patients with a prior history of severe hypoglycemia, exactly the population for whom Michigan Medicaid will approve a PA.

Mechanistically, degludec's flat pharmacokinetic profile has been quantified in euglycemic clamp studies. Day-to-day variability, measured as the within-subject coefficient of variation of the glucose infusion rate, was 20 percent lower for degludec than for glargine U-100 [2]. Lower variability translates directly into more predictable fasting glucose and lower hypoglycemia risk.

The Endocrine Society's clinical practice guideline on diabetes management states that basal insulin analogs with reduced hypoglycemia risk "should be considered for patients who have experienced one or more episodes of level 2 or level 3 hypoglycemia on current therapy" [13]. That guideline language maps directly to the Michigan Medicaid PA criteria described above.

Tresiba Dosing and Titration Basics

The starting dose for insulin-naive type 2 diabetes patients is 10 units subcutaneously once daily, injected at any time of day but at the same time each day [1]. For patients transferring from another basal insulin, the conversion is typically unit-for-unit from glargine or detemir, with a 20 percent dose reduction sometimes used when converting from high-dose insulin degludec or detemir to reduce early hypoglycemia risk.

Titration follows a treat-to-target approach. The standard Novo Nordisk algorithm titrates the dose by 2 units every three days based on the mean of three consecutive fasting glucose values. The fasting glucose target is typically 80 to 130 mg/dL per ADA 2024 targets, though individualized targets apply for older adults or patients with hypoglycemia unawareness [6].

Tresiba can be injected in the abdomen, thigh, or upper arm. Site rotation within the same region is recommended. The FlexTouch pen requires no priming beyond 2 units at initiation and delivers doses in 1-unit increments (U-100) or 2-unit increments (U-200).

Because degludec has a half-life exceeding 25 hours, missed doses should be taken as soon as remembered, provided the next scheduled dose is at least eight hours away [1]. This flexible dosing window is a practical advantage for patients with irregular schedules.

Pharmacy Access in Michigan

Tresiba is dispensed at retail and mail-order pharmacies throughout Michigan. Major chains including CVS, Walgreens, and Meijer Pharmacy stock Tresiba FlexTouch pens in both U-100 and U-200 concentrations at most locations. Availability can be verified through each chain's online pharmacy tool or by calling the specific store.

503A compounding pharmacies licensed in Michigan may also dispense insulin degludec when prepared in accordance with USP <797> sterile compounding standards [14]. A 503A pharmacy prepares compounds for individual patient prescriptions rather than in bulk. Patients choosing a 503A pharmacy should confirm the pharmacy holds a current Michigan Board of Pharmacy license and that the compounded insulin meets the prescriber's specified concentration and device requirements.

Mail-order options licensed to ship to Michigan include specialty pharmacy networks affiliated with most major PBMs. Mail-order typically requires a 90-day supply prescription and delivers within two to five business days after PA approval. Cost with copay assistance through Novo Nordisk's savings program (Novo Nordisk Patient Assistance) can bring the patient cost to as low as $99 per month for commercially insured patients [15].

Transferring a Tresiba Prescription to Michigan

Patients relocating to Michigan from another state can transfer a non-controlled substance prescription. Michigan pharmacy law permits a receiving pharmacist to accept a transferred prescription from an out-of-state pharmacy for a non-controlled medication, provided the transferring pharmacy cancels the original prescription upon transfer [16]. The patient contacts the new Michigan pharmacy, provides the name and phone number of the out-of-state pharmacy, and the pharmacies coordinate the transfer directly.

If the original prescriber is not licensed in Michigan, the transferring prescription serves only as a reference. A Michigan-licensed prescriber (in-person or telehealth) must write a new prescription to authorize refills. A telehealth appointment with a Michigan provider to review your current regimen and issue a new prescription is typically the fastest path to uninterrupted supply.

Patients using a CGM and a continuous glucose management platform such as Dexcom Clarity or LibreView can share their glucose reports digitally with the new Michigan telehealth provider before the appointment, reducing the visit time and allowing the provider to make an informed prescribing decision without ordering new labs if recent labs are already available [8].

Insurance Coverage and Cost in Michigan

Commercial insurance coverage for Tresiba in Michigan varies by plan. Blue Cross Blue Shield of Michigan's preferred drug list places insulin degludec on Tier 3 for most commercial plans, with a PA requirement [10]. Priority Health and McLaren Health Plan have similar tier structures. Out-of-pocket cost without insurance at a Michigan retail pharmacy runs approximately $350 to $450 for a 5-pen box (15 mL total) of Tresiba U-100.

Novo Nordisk's Tresiba savings card reduces cost to $99 per 30-day supply for eligible commercially insured patients [15]. Patients who are uninsured or underinsured may qualify for the Novo Nordisk Patient Assistance Program, which provides Tresiba at no cost to patients meeting income eligibility criteria (generally at or below 400 percent of the federal poverty level).

Michigan Medicaid (Healthy Michigan Plan) covers Tresiba with PA as described above. Once the PA is approved, the patient copay under Medicaid is typically $0 to $3 per prescription fill.

The Inflation Reduction Act insulin pricing provisions apply only to Medicare Part D; as of 2025, they cap Medicare Part D out-of-pocket insulin costs at $35 per month per covered insulin, which includes Tresiba for Medicare beneficiaries [17].